Zhongsheng Pharmaceutical: RAY1225 injection has been approved by the FDA to conduct phase II clinical trials for overweight or obese indications.

Zhongsheng Pharmaceutical stated on the interactive platform that it has received the drug clinical trial approval letter issued by the Food and Drug Administration of the United States for RAY1225 injection, allowing RAY1225 injection to be directly used in the United States for phase II clinical trials of overweight or obese indications. The company is actively seeking international cooperation, organizing international multicenter phase II clinical studies, and striving to complete relevant research as soon as possible in order to apply for drug market approval.